Economic Evaluation of Vaccination Programmes in Older Adults and the Elderly: Important Issues and Challenges
- 327 Downloads
High-income countries are undergoing demographic transitions towards populations with substantial larger proportions of older adults. Due to the increased susceptibility of older adults to infectious diseases and their consequences, vaccination programmes are an important health intervention to help maintain healthy ageing. While much of the existing literature suggests that current vaccination programmes targeted at older adults and the elderly are likely to be cost effective in high-income countries, we argue that it is important to more fully consider some important issues and challenges. Since the majority of vaccines have been developed for children, economic evaluations of vaccination programmes have consequentially tended to focus on this age group and on how to incorporate herd-immunity effects. While programmes targeted at older adults and the elderly may also induce some herd effects, there are other important challenges to consider in these economic evaluations. For example, age and time effects in relation to vaccine efficacy and duration of immunity, as well as heterogeneity between targeted individuals in terms of risk of infection, severity of disease and response to vaccination. For some pathogens, there is also the potential for interactions with childhood programmes in the form of herd-immunity effects.
KeywordsInfluenza Economic Evaluation Herpes Zoster Influenza Vaccine Vaccination Programme
This work was supported by an Australian National Health and Medical Research Council Project grant (1081344).
Anthony T. Newall initiated the idea for article; Sevan Dirmesropian carried out the review and drafted the initial manuscript. All authors contributed to planning the structure of the article and revising the manuscript, and approved the final version.
Compliance with Ethical Standards
Potential conflicts of interest
C. Raina MacIntyre has received in-kind support and funding for investigator-driven research from GlaxoSmithKline, Pfizer, Merck, and bioCSL, and has sat on advisory boards for Merck, GlaxoSmithKline and Pfizer. Sevan Dirmesropian, James G. Wood, Philippe Beutels, and Anthony T. Newall have no potential conflicts to declare.
- 1.The World Bank. High income countries: OECD. Available at: http://data.worldbank.org/income-level/OEC. Accessed 14 Jan 2016.
- 4.Pfuntner A, Wier LM Steiner C. Costs for hospital stay in the United States, 2010. Agency for Healthcare Research and Quality (HCUP), statistical brief #146. 2013. Available at: http://www.hcup-us.ahrq.gov/reports/statbriefs/sb146.pdf. Accessed Oct 2015.
- 7.Centres for Disease Control and Prevention. Active Bacterial Core Surveillance (ABC’s) report: emerging infection program network, Streptococcus pneumoniae surveillance report. Atlanta: Centres for Disease Control and Prevention; 2013.Google Scholar
- 9.Kawai K, Gebremeskel BG, Acosta CJ. Systematic review of incidence and complications of herpes zoster: towards a global perspective. BMJ Open. 2014;4(6):e004833.Google Scholar
- 13.Centers for Disease Control and Prevention (CDC). CDC vaccine price list. 1 May 2015. Available at: http://www.cdc.gov/vaccines/programs/vfc/awardees/vaccine-management/price-list/. Accessed 4 Jun 2015.
- 14.National Health and Medical Research Council (NHMRC). The Australian Immunisation Handbook 10th Edition. Canberra: Australian Government Department of Health and Ageing; 2013.Google Scholar
- 17.International Longevity Centre UK (ILC-UK). HERON. Cost effectiveness of adult immunization strategies: report. 2013. Available at: http://www.ilcuk.org.uk/index.php/publications/publication_details/adult_vaccination_a_key_component_of_healthy_ageing. Accessed Jan 2016.
- 29.Castilla J, et al. Decline in influenza vaccine effectiveness with time after vaccination, Navarre, Spain, season 2011/12. Euro Surveill. 2013;18(5) (pii:20388).Google Scholar
- 37.Moberley S, et al. Vaccines for preventing pneumococcal infection in adults. Cochrane Database Syst Rev. 2013;1(1):CD000422.Google Scholar
- 46.MacIntyre CR. Elderly vaccination: the glass is half full. Sci Res. 2013;5(12A):80–5.Google Scholar
- 48.Ultsch B, et al. Methods for health economic evaluation of vaccines and immunization decision frameworks: a consensus framework from a European vaccine economics community. Pharmacoeconomics (Epub 17 Oct 2015).Google Scholar
- 55.Smith KJ, et al. Modeling of cost effectiveness of pneumococcal conjugate vaccination strategies in US older adults. Am J Prevent Med. 2013;44(4):373–81.Google Scholar
- 56.Drummond MF, et al. Methods for the economic evaluation of helath care programmes. 3rd ed. Oxford: Oxford University Press; 2005.Google Scholar
- 62.Centers for Disease Control and Prevention, Advisory Committee on Immunization Practices. Recommended adult immunization schedule-United States. MMWR. 2012;61–84.Google Scholar
- 65.Australian Institute of Health and Welfare (AIHW). 2009 adult vaccination survey: summary results. 2011. Available at: http://www.aihw.gov.au/WorkArea/DownloadAsset.aspx?id=10737418286. Accessed Jan 2016.
- 68.Beutels P, et al. Seasonal influenza vaccination: prioritizing children or other target groups? Part II: cost effectiveness analysis. KCE report 204. 2013. Available at: https://kce.fgov.be/sites/default/files/page_documents/KCE_204_Seasonal_influenza_vaccination_partII.pdf. Accessed Jan 2016.
- 70.Van Den Hout WB. The value of productivity: human-capital versus friction-cost method. Ann Rheum Dis. 2010;69(Suppl. 1):i89–i91.Google Scholar
- 73.Australian Bureau of Statistics (ABS). Life tables, states, territories and Australia, 2011–2013. 2014. Available at: http://www.abs.gov.au/AUSSTATS/abs@.nsf/DetailsPage/3302.0.55.0012011-2013?OpenDocument. Accessed 15 Jun 2015.
- 78.Vynnycky E, White RG. An introduction to infectious disease modelling. Oxford: Oxford University Press; 2011.Google Scholar